DOCSLIB.ORG

I. Understanding Membrane Interactions of Bacterial Exoproteins; II

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I. Understanding Membrane Interactions of Bacterial Exoproteins; II I. Understanding Membrane Interactions of Bacterial Exoproteins; II. Identification and Characterization of a Novel Mammalian cis-Aconitate Decarboxylase Author: Jiongjia Cheng Persistent link: http://hdl.handle.net/2345/bc-ir:104068 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2013 Copyright is held by the author, with all rights reserved, unless otherwise noted. Boston College The Graduate School of Arts and Sciences Department of Chemistry I. UNDERSTANDING MEMBRANE INTERACTIONS OF BACTERIAL EXOPROTEINS; II. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL MAMMALIAN CIS- ACONITATE DECARBOXYLASE A Dissertation by JIONGJIA CHENG Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy December, 2013 © copyright by JIONGJIA CHENG 2013 I. Understanding Membrane Interactions of Bacterial Exoproteins; II. Identification and Characterization of a Novel Mammalian cis-Aconitate Decarboxylase Jiongjia Cheng Under the direction of Dr. Mary F. Roberts ABSTRACT Secreted phosphatidylinositol-specific phospholipase Cs (PI-PLCs) are often virulence factors in pathogenic bacteria. Understanding how these enzymes interact with target membranes may provide novel methods to control bacterial infections. In this work, two typical PI-PLC enzymes, from Bacillus thuringiensis (Bt) and Staphylococcus aureus (Sa), were studied and their membrane binding properties were examined and correlated with enzymatic activity. BtPI-PLC is kinetically activated by allosteric binding of a phosphatidylcholine (PC) molecule. MD simulations of the protein in solution suggested correlated loop and helix motions around the active site could regulate BtPI-PLC activity. Vesicle binding and enzymatic studies of variants of two proline residues, Pro245 and Pro254, that were associated with these motions showed that loss of the correlated motions between the two halves of PI-PLC were more critical for enzymatic activity than for vesicle binding. Furthermore, loss of enzyme activity could be rescued to a large extent with PC present in a vesicle. This suggests that binding to PC changes the enzyme conformation to keep the active site accessible. SaPI-PLC shows 41.3% sequence similarity with BtPI-PLC but has very different ways its activity is regulated. While it is kinetically activated by PC it does not in fact bind to that phospholipid. Enzymatic and membrane interaction assays showed that SaPI-PLC has evolved a complex, apparently unique way to control its access to PI or GPI-anchored substrate. (i) An intramolecular cation-π latch facilitates soluble product release under acidic conditions without dissociation from the membrane. (ii) There is a cationic pocket on the surface of enzyme that likely modulates the location of the protein. (iii) Dimerization of protein is enhanced in membranes containing phosphatidylcholine (PC), which acts not by specifically binding to the protein, but by reducing anionic lipid interactions with the cationic pocket that stabilizes monomeric protein. SaPI-PLC activity is modulated by competition between binding of soluble anions or anionic lipids to the cationic sensor and transient dimerization on the membrane depleted in anionic phospholipids. This protein also served as a way to test the hypothesis that a cation-π box provides for PC recognition site. This structural motif was engineered into SaPI-PLC by forming N254Y/H258Y. This variant selectively binds PC-enriched vesicles and the enzyme binding behavior mimics that of BtPI-PLC. Itaconic acid (ITA) is a metabolite synthesized in macrophages and related cell lines by a cis-aconitate decarboxylase (cADC). cADC activity is dramatically increased upon macrophage stimulation. In this work, the cell line RAW264.7 was used to show that cADC activity upon stimulation requires de novo protein synthesis. MS analyses of partially purified RAW264.7 protein extracts from stimulated cells show a large increase for immunoresponsive gene 1 protein (IRG1) and siRNA knockdown of the IRG1 reduces cADC activity upon stimulation. Suspected active site residues of IRG1 were identified by mutagenesis studies of the recombinant protein based on a homology structure model of fungal cADC. The cloning and overexpression of this enzyme should help clarify the cofactor-independent decarboxylation mechanism of this mammalian enzyme as well as open up future studies into the specific role of ITA in the mammalian immune system and cancers. Acknowledgements First and foremost, I would like to especially thank my adviser Prof. Mary F. Roberts for her guidance and support during my Ph.D. studies. She is always encouraging, giving me confidence and offering invaluable advice in my research. I am so proud to be her student and her extraordinary personality made my graduate studies enjoyable and will influence me for the rest of my life. I would like to thank all the collaborators for their contributions in this work: Prof. Anne Gershenson for her guidance and help in the PI-PLC projects, especially for the use of FCS instrument; Prof. Patrick L. Wintrode and Prof. Nathalie Reuter for their MD simulations of BtPI-PLC; Dr. Boguslaw Stec for his help in protein crystallization and structural modeling; Prof. Thomas Chiles for his guidance in mammalian cell culture; and Prof. Eranthie Weerapana for her help in the MS proteomics study. Special thanks are expressed to Dr. Fay Dufort and Shannon Heyse, who gave me helpful advice on cell biology techniques. These collaborative experiences were especially valuable to me. I would like to thank all the members of Roberts group, the present and the past, for their friendship and helpful discussions. I would like to give special thanks to Dr. Rebecca Goldstein for her work in the crystallization of SaPI-PLC. I would also like to thank Dr. Mingming Pu and Dr. Xiaomeng Shi for their guidance in my research during my first year; Dr. Cheryl L. Strelko for her advice in cADC identification, and Delilah Jewel for her help in RAW cell growth and cADC mutagenesis. I shared a lot of fun time with Dr. Wei Chen, Dr. Su Guo, Dr. Yang Wei, Dr. Jingfei Cai and Tao He, and they all provided me with useful suggestions. Lastly and most importantly, I want to thank my parents for their love and care during my whole life. I also want to thank my husband, Qian, for his love, support and encouragement, and for the happiness he brings to my life. My daughter, Emily, although only 6 months, does bring me a lot of happiness, and I would like to thank her too. Abbreviations A. terreus Aspergillus terreus ActD actinomycin D AF488-Cys Alexa Fluor 488 C5 maleimide AF488-N-term Alexa Fluor 488 carboxylic acid, succinimidyl ester APS ammonium persulfate B. cereus Bacillus cereus B. thuringiensis Bacillus thuringiensis BSA bovine serum albumin BtPI-PLC Bacillus thuringiensis phosphatidylinositol-specific phospholipase C C2 protein kinase C conserved region 2 cADC cis-aconitate decarboxylase CBD chitin binding domain CD circular dichroism cDNA complementary deoxyribonucleic acid cIP inositol 1,2-cyclic phosphate CMC critical micelle concentration CNS central nervous system CoA coenzyme A CSA chemical shift anisotropy i D2O deuterium oxide DAG diacylglycerol DC detergent compatible diC6PC dihexanoyl-phosphatidylcholine diC7PC diheptanoyl-phosphatidylcholine diC8PE dioctanoyl-phosphatidylethanolamine diC8PG dioctanoyl-phosphatidyglycerol diC8PS dioctanoyl-phosphatidylseine DLS dynamic light scattering DMEM Dulbecco’s minimal essential medium DMPC 1,2-dimyristoyl-phosphocholine DMSO dimethyl sulfoxide DOPA 1,2-dioleoyl-phosphatidic acid DOPG 1,2-dioleoyl-phosphatidyglycerol DOPMe 1,2-dioleoyl-phosphatidylmethanol DOPS 1,2-dioleoyl-phosphatidylserine dsRNA double-stranded RNA DTNB 5,5'-dithiobis-(2-nitrobenzoic acid) DTT dithiothreitol E. coli Escherichia coli EDTA ethylenediaminetetraacetic acid EGF epidermal growth factor ii FBS fetal bovine serum fc-P-NMR high resolution field cycling 31P NMR FCS fluorescence correlation spectroscopy fmax apparent maximum fraction bound FRET fluorescence resonance energy transfer GPI glycosylphosphatidylinositol GST glutathione S-transferase HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HIC hydrophobic interaction chromatography His-tag poly histidine tag I-1-P inositol 1-phosphate IDS iminodisuccinate IFN-γ interferon γ IMPDH inosine monophosphate dehydrogenase IPTG isopropyl β-D-1-thiogalactopyranoside IRG1 immunoresponsive gene 1 ITA itaconic acid Kd apparent dissociation constant Km Michaelis constant L. monocytogenes Listeria monocytogenes LAB lactic acid bacteria LP lipopeptide or lipoprotein iii LPS lipopolysaccharide MBP maltose-binding protein MD molecular dynamics MES 2-(N-morpholino) ethane-sulfonic acid MS mass spectrometry MSA multiple sequence alignment MTSL 1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl-methanethio- sulfonate MyD88 myeloid differentiation factor-88 NAD+ β-nicotinamide adenine dinucleotide hydrate NF-κB nuclear factor κ-light-chain-enhancer of activated B cells Ni-NTA nickel-nitrilotriacetic acid NMR nuclear magnetic resonance NOS nitric oxide O.D. optical density ORF open reading frame PA phosphatidic acid PBS phosphate buffered saline PC phosphatidylcholine PCA principal component analyses PCR polymerase chain reaction PE phosphatidylethanolamine iv PG phosphatidylglycerol PH pleckstrin homology pI isoelectric point PI phosphatidylinositol PI3K phosphatidylinositol 3-kinase PIA phosphatidylinositol analog PI-PLC phosphatidylinositol-specific
Load more

Recommended publications
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene Et Al
    US 20090292100A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene et al. (43) Pub. Date: Nov. 26, 2009 (54) PROCESS FOR PREPARING (86). PCT No.: PCT/EP07/57646 PENTAMETHYLENE 1.5-DIISOCYANATE S371 (c)(1), (75) Inventors: Martin Fiene, Niederkirchen (DE): (2), (4) Date: Jan. 9, 2009 (DE);Eckhard Wolfgang Stroefer, Siegel, Mannheim (30) Foreign ApplicationO O Priority Data Limburgerhof (DE); Stephan Aug. 1, 2006 (EP) .................................. O61182.56.4 Freyer, Neustadt (DE); Oskar Zelder, Speyer (DE); Gerhard Publication Classification Schulz, Bad Duerkheim (DE) (51) Int. Cl. Correspondence Address: CSG 18/00 (2006.01) OBLON, SPIVAK, MCCLELLAND MAIER & CD7C 263/2 (2006.01) NEUSTADT, L.L.P. CI2P I3/00 (2006.01) 194O DUKE STREET CD7C 263/10 (2006.01) ALEXANDRIA, VA 22314 (US) (52) U.S. Cl. ........... 528/85; 560/348; 435/128; 560/347; 560/355 (73) Assignee: BASFSE, LUDWIGSHAFEN (DE) (57) ABSTRACT (21) Appl. No.: 12/373,088 The present invention relates to a process for preparing pen tamethylene 1,5-diisocyanate, to pentamethylene 1,5-diiso (22) PCT Filed: Jul. 25, 2007 cyanate prepared in this way and to the use thereof. US 2009/0292100 A1 Nov. 26, 2009 PROCESS FOR PREPARING ene diisocyanates, especially pentamethylene 1,4-diisocyan PENTAMETHYLENE 1.5-DIISOCYANATE ate. Depending on its preparation, this proportion may be up to several % by weight. 0014. The pentamethylene 1,5-diisocyanate prepared in 0001. The present invention relates to a process for pre accordance with the invention has, in contrast, a proportion of paring pentamethylene 1,5-diisocyanate, to pentamethylene the branched pentamethylene diisocyanate isomers of in each 1.5-diisocyanate prepared in this way and to the use thereof.
    [Show full text]
  • Myeloid Innate Immunity Mouse Vapril2018
    Official Symbol Accession Alias / Previous Symbol Official Full Name 2810417H13Rik NM_026515.2 p15(PAF), Pclaf RIKEN cDNA 2810417H13 gene 2900026A02Rik NM_172884.3 Gm449, LOC231620 RIKEN cDNA 2900026A02 gene Abcc8 NM_011510.3 SUR1, Sur, D930031B21Rik ATP-binding cassette, sub-family C (CFTR/MRP), member 8 Acad10 NM_028037.4 2410021P16Rik acyl-Coenzyme A dehydrogenase family, member 10 Acly NM_134037.2 A730098H14Rik ATP citrate lyase Acod1 NM_008392.1 Irg1 aconitate decarboxylase 1 Acot11 NM_025590.4 Thea, 2010309H15Rik, 1110020M10Rik,acyl-CoA Them1, thioesterase BFIT1 11 Acot3 NM_134246.3 PTE-Ia, Pte2a acyl-CoA thioesterase 3 Acox1 NM_015729.2 Acyl-CoA oxidase, AOX, D130055E20Rikacyl-Coenzyme A oxidase 1, palmitoyl Adam19 NM_009616.4 Mltnb a disintegrin and metallopeptidase domain 19 (meltrin beta) Adam8 NM_007403.2 CD156a, MS2, E430039A18Rik, CD156a disintegrin and metallopeptidase domain 8 Adamts1 NM_009621.4 ADAM-TS1, ADAMTS-1, METH-1, METH1a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1 Adamts12 NM_175501.2 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 12 Adamts14 NM_001081127.1 Adamts-14, TS14 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 14 Adamts17 NM_001033877.4 AU023434 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 17 Adamts2 NM_001277305.1 hPCPNI, ADAM-TS2, a disintegrin and ametalloproteinase disintegrin-like and with metallopeptidase thrombospondin
    [Show full text]
  • Enzymatic Reaction Mechanism of Cis-Aconitate Decarboxylase Based
    www.nature.com/scientificreports OPEN Enzymatic reaction mechanism of cis‑aconitate decarboxylase based on the crystal structure of IRG1 from Bacillus subtilis Hye Lin Chun1, So Yeon Lee1, Sung Hoon Lee1, Chang Sup Lee2 & Hyun Ho Park1* Itaconate, which is formed by decarboxylation of cis‑aconitate—an intermediate metabolite in the tricarboxylic acid cycle—has been used as a building block in polymer synthesis and is an important chemical in several biomedical and industrial applications. Itaconate is an immunometabolite with antibacterial, antiviral, immunoregulatory, and tumor‑promoting activities. Recent focus has been on the role of itaconate in the feld of immunology, with immune-responsive gene 1 (IRG1) being identifed as the cis‑aconitate decarboxylase responsible for itaconate production. We solved the structure of IRG1 from Bacillus subtilis (bsIRG1) and showed that IRG1 adopts either a closed or an open conformation; bsIRG1 was in the open form. A1 and A2 loops around the active site are fexible and can control the formation of the open and closed forms of IRG1. An in silico docking simulation showed that only the open form of IRG1 can accommodate the substrate. The most energetically favorable position of cis-aconitate in the active site of bsIRG1 involved the localization of C2 and C5 of cis-aconitate into the H102 region and H151 region of bsIRG1, respectively. Based on the structural study of bsIRG1, compared with IDS epimerase, and in silico docking simulation, we proposed two tentative enzymatic reaction mechanisms of
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Escherichia Coli As a Host for Metabolic Engineering
    Metabolic Engineering xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Metabolic Engineering journal homepage: www.elsevier.com/locate/meteng Escherichia coli as a host for metabolic engineering Sammy Pontrellia, Tsan-Yu Chiub, Ethan I. Lanc, Frederic Y.-H. Chena,b, Peiching Changd,e, ⁎ James C. Liaob, a Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, USA b Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan c Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan d Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan e Material and Chemical Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan ABSTRACT Over the past century, Escherichia coli has become one of the best studied organisms on earth. Features such as genetic tractability, favorable growth conditions, well characterized biochemistry and physiology, and avail- ability of versatile genetic manipulation tools make E. coli an ideal platform host for development of industrially viable productions. In this review, we discuss the physiological attributes of E. coli that are most relevant for metabolic engineering, as well as emerging techniques that enable efficient phenotype construction. Further, we summarize the large number of native and non-native products that have been synthesized by E. coli, and address some of the future challenges in broadening substrate range and fighting phage infection. 1. Introduction acids which has traditionally been produced from the natural producer Corynebacterium glutamicum (Gusyatiner et al., 2017). E. coli production Escherichia coli is a Gram-negative, facultative anaerobic bacterium of n-butanol has also been demonstrated to the level similar to that originally discovered in the human colon in 1885 by German bacter- produced in Clostridia (Shen et al., 2011; Ohtake et al., 2017).
    [Show full text]
  • Gene Ontology
    Protein Function Prediction Protein function - field of biochemists • can it be predicted / guessed from • structure ? • sequence ? Is this an issue ? • 5 to 10 years ago • a protein was of interest, because one knew its function • then found its sequence + structure • now, lots of proteins unknown Andrew Torda, Wintersemester 2015 / 2016, Angewandte … Andrew Torda 23.11.2016 [ 1 ] Example yeast genome Yeast 6.6 × 103 proteins / ORFs ≈ decade after sequencing Not really known what many proteins do Protein function may not be easy • extreme case - prions • structure lots of effort (X-ray, NMR) • function - expression, knockouts • function still not really clear Hirschman, J. E. et al. Nucl. Acids Res. 2006 34, D442-D445 Andrew Torda 23.11.2016 [ 2 ] e. coli Color Gene Role Category 1 Amino acid biosynthesis 3.16 % 2 Biosynthesis of cofactors, prosthetic groups, and carriers 2.67 % 3 Cell envelope 6.90 % 4 Cellular processes 6.01 % 5 Central intermediary metabolism 3.33 % 6 Disrupted reading frame 0.84 % 7 DNA metabolism 5.07 % 8 Energy metabolism 7.92 % 9 Fatty acid and phospholipid metabolism 1.20 % 10 gene/protein expression 0 % 11 Hypothetical proteins 3.65 % 12 Hypothetical proteins - Conserved 18.0 % 13 metabolism 0 % 14 Mobile and extrachromosomal element functions 5.96 % 15 Pathogen responses 0 % 16 Protein fate 4.18 % 17 Protein synthesis 6.14 % 18 Purines, pyrimidines, nucleosides, and nucleotides 2.71 % 19 Regulatory functions 6.50 % 20 Signal transduction 1.20 % 21 Transcription 1.02 % 22 Transport and binding proteins 12.2
    [Show full text]
  • Does DNA Methylation Level Play a Role?
    Epigenetic regulation of Verticillium dahliae virulence: does DNA methylation level play a role? Jorge A. Ramírez-Tejero1, Carmen Gómez-Lama Cabanás2, Antonio Valverde- Corredor2, Jesús Mercado-Blanco2 and Francisco Luque1* 1Center for Advanced Studies in Olive Grove and Olive Oils, Department of Experimental Biology, Univ. Jaén, 23071-Jaén, Spain 2Department of Crop Protection, Institute for Sustainable Agriculture, Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC), Campus ‘Alameda del Obispo’, Avenida Menéndez Pidal s/n, Apartado 14004 Córdoba, Spain Email: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]. *Corresponding author F. Luque, [email protected]. ORCiD ID: 0000-0003-1354-3533 Table S1 937‐HP_NODE_NU GENE NAME GENE LENGDIFF % 937‐138_NODE_NUMGENE LE DIFF % 937‐150_NODE_NGENE LE DIFF % 937‐403_NODE_NGENE LENDIFF % 100g0000040.1 Unknown protein 2903 55 1,894591802 100g0000040.1 2903 ‐197,5 ‐6,803306924 100g0000040.1 2903 41,5 1,429555632 100g0000040.1 2903 ‐68 ‐2,342404409 100g0000050.1 Unknown protein 2732 66 2,415812592 100g0000050.1 2732 ‐133 ‐4,868228404 100g0000050.1 2732 69,5 2,543923865 100g0000050.1 2732 ‐44,5 ‐1,628843338 100g0000060.1 Unknown protein 1986 27,5 1,38469285 100g0000060.1 1986 ‐108,5 ‐5,463242699 100g0000060.1 1986 36 1,812688822 100g0000060.1 1986 ‐27 ‐1,359516616 100g0000190.1 Unknown protein 569 60 10,54481547 100g0000190.1 569 ‐26 ‐4,569420035 100g0000190.1 569 24 4,217926186 100g0000190.1 569 ‐12,5 ‐2,196836555 1013g0000010.1
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,017,983 B2 Burgard Et Al
    US009017983B2 (12) United States Patent (10) Patent No.: US 9,017,983 B2 Burgard et al. (45) Date of Patent: Apr. 28, 2015 (54) ORGANISMS FOR THE PRODUCTION OF 5,521,075 A 5/1996 Guettler et al. 13-BUTANEDOL 5,573.931 A 11/1996 Guettler et al. 9 5,616,496 A 4/1997 Frost et al. 5,661,026 A 8/1997 Peoples et al. (75) Inventors: Anthony P. Burgard, Bellefonte, PA 5,686,276 A 1 1/1997 Lafend et al. (US); Mark J. Burk, San Diego, CA 5,700.934. A 12/1997 Wolters et al. (US); Robin E. Osterhout, San Diego, 5,770.435 A 6/1998 Donnelly et al. t sS); Priti Pharkya, San Diego, CA (Continued) FOREIGN PATENT DOCUMENTS (73) Assignee: Genomatica, Inc., San Diego, CA (US) CN 1358 841 T 2002 (*) Notice: Subject to any disclaimer, the term of this EP O 494 O78 7, 1992 patent is extended or adjusted under 35 E. s 29: U.S.C. 154(b) by 654 days. GB 1230276 4f1971 GB 1314126 4f1973 (21) Appl. No.: 12/772,114 GB 1344557 1, 1974 GB 1512751 6, 1978 (22) Filed: Apr. 30, 2010 JP 50 OO6776 1, 1975 WO WO 82,03854 11, 1982 (65) Prior Publication Data (Continued) US 2010/033.0635A1 Dec. 30, 2010 OTHER PUBLICATIONS Related U.S. Application Data Abadjieva et al., “The Yeast ARG7 Gene Product is Autoproteolyzed (60) Provisional application No. 61/174,473, filed on Apr. to Two Subunit Peptides, Yielding Active Ornithine 30, 2009 Acetyltransferase.” J. Biol.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • Sequence Homology • Structure Homology • Sequence Patterns / Motifs • Structure Patterns / Motifs
    Protein Function Prediction Protein function - field of biochemists • can it be predicted / guessed from • structure ? • sequence ? Is this an issue ? • 5 to 10 years ago • a protein was of interest, because one knew its function • then found its sequence + structure • now, lots of proteins unknown Andrew Torda, Wintersemester 2015 / 2016, Angewandte … Andrew Torda 18.11.2015 [ 1 ] Example yeast genome Yeast 6.6 × 103 proteins / ORFs ≈ decade after sequencing Not really known what many proteins do Protein function may not be easy • extreme case - prions • structure lots of effort (X-ray, NMR) • function - expression, knockouts • function still not really clear Hirschman, J. E. et al. Nucl. Acids Res. 2006 34, D442-D445 Andrew Torda 18.11.2015 [ 2 ] e. coli Color Gene Role Category 1 Amino acid biosynthesis 3.16 % 2 Biosynthesis of cofactors, prosthetic groups, and carriers 2.67 % 3 Cell envelope 6.90 % 4 Cellular processes 6.01 % 5 Central intermediary metabolism 3.33 % 6 Disrupted reading frame 0.84 % 7 DNA metabolism 5.07 % 8 Energy metabolism 7.92 % 9 Fatty acid and phospholipid metabolism 1.20 % 10 gene/protein expression 0 % 11 Hypothetical proteins 3.65 % 12 Hypothetical proteins - Conserved 18.0 % 13 metabolism 0 % 14 Mobile and extrachromosomal element functions 5.96 % 15 Pathogen responses 0 % 16 Protein fate 4.18 % 17 Protein synthesis 6.14 % 18 Purines, pyrimidines, nucleosides, and nucleotides 2.71 % 19 Regulatory functions 6.50 % 20 Signal transduction 1.20 % 21 Transcription 1.02 % 22 Transport and binding proteins 12.2
    [Show full text]